the aid library

LIST OPTIONS

Filter

7431

Sort by:

Direction:

Download (1085)

View PDF (1723)

Basic Newborn Resuscitation: A Practical Guide

World Health Organization Word Health Organization (1997) C_WHO

Safe Motherhood Series

Download (164)

View PDF (212)

Roadmap to improve and ensure good indoor ventilation in the context of COVID-19

World Health Organization WHO (2021) C_WHO

1 March 2021 This roadmap aims to define the key questions users should consider to assess indoor ventilation and the major steps needed to reach recommended ventilation levels or simply improve indoor air quality (IAQ) in order to reduce the risk of spread of COVID-19. It also includes recommendat... more

Download (120)

View PDF (149)

Use of non-sugar sweeteners: WHO guideline

World Health Organisation (WHO) World Health Organisation (WHO) (2023) C_WHO

This guideline provides evidence-informed guidance on the use of non-sugar sweeteners to reduce the risk of unhealthy weight gain and diet-related noncommunicable diseases in adults and children. The guidance in this guideline is not based on toxicological assessments of the safety of individual no... more

Download (68)

View PDF (41)

Module for Multi-Purpose Workers (MPW) - Female/Male on Prevention, Screening and Control of Common Non-Communicable Diseases

National Health Mission; Minister of Health and Family Welfare Government of India (2024) CC2

This module covers common Non-Communicable Diseases such as Hypertension, Diabetes and three common cancers (Cervical, Breast and Oral cancer). The focus of this module is on building the knowledge and skills of the Multi-Purpose Workers (MPW) in undertaking Population Based Screening, identifi ca... more

Download (50)

View PDF (35)

Management of type 2 diabetes in adults

Department of Health: Republic of South Africa (2014) CC2

Diabetes is a major public health problem. The rising incidence of Diabetes Type 2 is related to the effects of urbanization and unhealthy lifestyles. Research studies show that healthy eating and regular physical activity can prevent or delay the onset of Diabetes Type 2, even in high-risk individu... more

Download (37)

View PDF (48)

Infrastructure, policy and regulatory interventions to increase physical activity to prevent cardiovascular diseases and diabetes: a systematic review

Durão, S.; Burns, J.; Schmidt, B. et al. BMC Public Health (2023) CC

Background Noncommunicable diseases are major contributors to morbidity and mortality worldwide. Modifying the risk factors for these conditions, such as physical inactivity, is thus essential. Addressing the context or circumstances in which physical activity occurs may promote physical activity a...t a population level. We assessed the effects of infrastructure, policy or regulatory interventions for increasing physical activity. Methods We searched PubMed, Embase and clinicaltrials.gov to identify randomised controlled trials (RCTs), controlled before-after (CBAs) studies, and interrupted time series (ITS) studies assessing population-level infrastructure or policy and regulatory interventions to increase physical activity. We were interested in the effects of these interventions on physical activity, body weight and related measures, blood pressure, and CVD and type 2 diabetes morbidity and mortality, and on other secondary outcomes. Screening and data extraction was done in duplicate, with risk of bias was using an adapted Cochrane risk of bias tool. Due to high levels of heterogeneity, we synthesised the evidence based on effect direction. Results We included 33 studies, mostly conducted in high-income countries. Of these, 13 assessed infrastructure changes to green or other spaces to promote physical activity and 18 infrastructure changes to promote active transport. The effects of identified interventions on physical activity, body weight and blood pressure varied across studies (very low certainty evidence); thus, we remain very uncertain about the effects of these interventions. Two studies assessed the effects of policy and regulatory interventions; one provided free access to physical activity facilities and showed that it may have beneficial effects on physical activity (low certainty evidence). The other provided free bus travel for youth, with intervention effects varying across studies (very low certainty evidence). Conclusions Evidence from 33 studies assessing infrastructure, policy and regulatory interventions for increasing physical activity showed varying results. The certainty of the evidence was mostly very low, due to study designs included and inconsistent findings between studies. Despite this drawback, the evidence indicates that providing access to physical activity facilities may be beneficial; however this finding is based on only one study. Implementation of these interventions requires full consideration of contextual factors, especially in low resource settings. more

Download (182)

View PDF (259)

HEARTS. Tool for the development of a consensus protocol for treatment of hypertension

World Health Organization WHO, et al. (2018) C_WHO

Technical package for cardiovascular disease management in primary health care.

Download (44)

View PDF (107)

WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more

Download (121)

View PDF (118)

Global technical consultation report on proposed terminology for pathogens that transmit through the air

World Health Organization WHO (2024) C_WHO

Terminology used to describe the transmission of pathogens through the air varies across scientific disciplines, organizations and the general public. While this has been the case for decades, during the coronavirus disease (COVID-19) pandemic, the terms ‘airborne’, ‘airborne transmission’ a... more

Download (273)

View PDF (368)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (116)

View PDF (123)

Tuberculosis Research Funding Trends 2005-2020

World Health Organisation (WHO) (2021) C_WHO

Previous advocacy efforts have achieved tangible goals in terms garnering political commitments to increase financing for TB—as seen at the 2018 UN High-Level Meeting on TB. The challenge now is to ensure that these commitments are actually met within a global biomedical research ecosystem that... more

Download (247)

View PDF (201)

Case definitions, clinical classification, and disease phases Dengue, Chikungunya, and Zika
recommended

World Health Organisation (WHO) (2023) C_WHO

A person who lives in or has traveled in the previous 14 days to areas with dengue transmission, and presents with acute fever that has typically lasted 2 to 7 days, and two or more of the following clinical manifestations: nausea or vomiting, exanthema, headache or retro-orbital pain, myalgia or ar... more

Download (156)

View PDF (173)

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

Download (369)

View PDF (275)

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. F10 - F19 Mental and behavioural disorders due to psychoactive substance use

World Health Organization (WHO) (1992) C_WHO

This block contains a wide variety of disorders that differ in severity (from uncomplicated intoxication and harmful use to obvious psychotic disorders and dementia), but that are all attributable to the use of one or more psychoactive substances (which may or may not have been medically prescribed)

Download (248)

View PDF (309)

Self-harm/suicide: Powerpoint presentation slides (mhGAP)

World Health Organization WHO (2015) C_WHO

Session outline •Introduction to self-harm/suicide. •Assessment of self-harm/suicide. •Management of self-harm/suicide. •Follow-up.

Download (687)

View PDF (596)

Depression: Powerpoint Presentation slides (mhGAP)
recommended

World Health Organization (WHO) (2015) C_WHO

Session outline •Introduction to depression •Assessment of depression •Management of depression •Follow-up •Review

Download (135)

View PDF (156)

Recommended package of interventions for HIV, viral hepatis and STI prevention, diagnosis, treatment and care for people who inject drugs: policy brief

World Health Organisation (WHO) (2023) C_WHO

HIV, viral hepatitis and STI epidemics, particularly among people who inject drugs and other key populations, continue to be fuelled by laws and policies criminalizing sex work; drug use or possession; diverse forms of gender expression and sexuality; stigma and discrimination; gender discrimination... more

Download (1218)

View PDF (2725)

Guide to Local Production: WHO-recommended Handrub Formulations
recommended

World Health Organization WHO (2010) C_WHO

This guide to local production of WHO-recommended handrub formulations is separated into two discrete but interrelated sections: Part A provides a practical guide for use at the pharmacy bench during the actual preparation of the formulation. Users may want to display the material on the wall of ... more

Download (152)

View PDF (220)

A WHO Guide to the Implementation of the WHO Multimodal Hand Hygiene Improvement Strategy

World Health Organization WHO (2009) C_WHO

Health care-associated infection (HCAI) places a serious disease burden and has a significant economic impact on patients and health-care systems throughout the world. Yet good hand hygiene, the simple task of cleaning hands at the right times and in the right way, can save lives. World Health O... more

Download (156)

View PDF (187)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

Case definitions, clinical classification, and disease phases Dengue, Chikungunya, and Zika recommended

Depression: Powerpoint Presentation slides (mhGAP) recommended

Guide to Local Production: WHO-recommended Handrub Formulations recommended

Case definitions, clinical classification, and disease phases Dengue, Chikungunya, and Zika
recommended

Depression: Powerpoint Presentation slides (mhGAP)
recommended

Guide to Local Production: WHO-recommended Handrub Formulations
recommended